<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04980027</url>
  </required_header>
  <id_info>
    <org_study_id>LPS16665</org_study_id>
    <secondary_id>U1111-1255-5143</secondary_id>
    <nct_id>NCT04980027</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs</brief_title>
  <acronym>SAFEGUARD</acronym>
  <official_title>Multicentre Phase IV Single Arm Clinical Trial to evaluAte the saFety and Efficacy of Gla-300 in insUlin-naïve Patients With Type 2 DiAbetes uncontRolled on Oral Antihyperglycemic Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To evaluate the safety of Gla-300 in insulin naïve T2D participants uncontrolled on oral&#xD;
      antihyperglycemic drugs&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      To assess the efficacy of Gla-300 on glycemic control in insulin naïve T2D participants&#xD;
      uncontrolled on oral anti-hyperglycemic drugs To assess change in participant's treatment&#xD;
      satisfaction using DTSQs (Diabetes Treatment Satisfaction Questionnaire)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The maximum study duration per participant is 27 weeks including a screening period of up to&#xD;
      2 weeks, a 24-week treatment period and a post-treatment follow-up phone call visit after 3&#xD;
      days after the end of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>TEAEs including serious adverse events (SAEs) and hypoglycemic episode</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with at least one confirmed hypoglycemia event</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from Baseline to week 12 and week 24</measure>
    <time_frame>Baseline to Week 12 and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants reaching HbA1c target of &lt;7%</measure>
    <time_frame>Week 12 and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants reaching targeted fasting self-monitored blood glucose (SMBG) of 80 to 110 mg/dL (4.4 to 6.1 mmol/L)</measure>
    <time_frame>Week 12 and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose (FPG) from Baseline to Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting SMBG from Baseline to Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 7-point SMBG profile from Baseline to Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants requiring rescue therapy</measure>
    <time_frame>Week 12 and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight from Baseline to Week 12 and Week 24</measure>
    <time_frame>Baseline to Week 12 and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin dose from Baseline to Week 12 and Week 24</measure>
    <time_frame>Baseline to Week 12 and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DTSQs scores from Baseline to Week 12 and Week 24</measure>
    <time_frame>Baseline to Week 12 and Week 24</time_frame>
    <description>The Diabetes Treatment Satisfaction Questionnaire - status version (DTSQs) is measuring patients' satisfaction with their diabetes treatment.Total treatment satisfaction score range from 0 (no satisfaction) to 36 (improvement in treatment satisfaction)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Insuline Glargine (U300) (Gla-300)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin glargine (U300) once daily for 24 weeks on top of non-insulin antidiabetic drug. Insulin dose will be adjusted according to the recommended titration algorithm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine (U300)</intervention_name>
    <description>Pharmaceutical form:Solution for injection in a prefilled pen Route of administration: Subcutaneous</description>
    <arm_group_label>Insuline Glargine (U300) (Gla-300)</arm_group_label>
    <other_name>HOE901 Toujeo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Participants with Type 2 diabetes mellitus&#xD;
&#xD;
          -  Participants who are insulin naïve on at least one oral antihyperglycemic drug&#xD;
             (metformin,sulfonylurea, thiazolidinedione, DPP-4 inhibitor, SGLT-2 inhibitor,&#xD;
             glinide, α-glucosidase inhibitor) with or without glucagon-like peptide 1 receptor&#xD;
             agonists (GLP-1 RAs) for a minimum period of 6 months prior to screening.&#xD;
&#xD;
          -  HbA1c between 7.5% (58 mmol/mol) and 10% (86 mmol/mol) inclusive, during screening.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of severe hypoglycemia requiring emergency room admission or hospitalization&#xD;
             within 3 months prior to screening visit.&#xD;
&#xD;
          -  Proliferative retinopathy or maculopathy requiring treatment according to the&#xD;
             Investigator&#xD;
&#xD;
          -  Treatment with any insulin including basal insulin, mixed insulin (premixes), rapid&#xD;
             insulin, and fast-acting insulin analogues in the last 6 months before screening visit&#xD;
             (use ≤10 days in relation to hospitalization or an acute illness is accepted).&#xD;
&#xD;
          -  Use of systemic glucocorticoids (excluding topical application or inhaled forms) for 2&#xD;
             weeks or more within 8 weeks prior to screening visit.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational site Number 3560003</name>
      <address>
        <city>Jaipur</city>
        <zip>302017</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site Number 3560013</name>
      <address>
        <city>Nasik</city>
        <zip>422002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

